MX390748B - Composiciones y metodos para tratar accidente cerebrovascular isquemico. - Google Patents

Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Info

Publication number
MX390748B
MX390748B MX2018006390A MX2018006390A MX390748B MX 390748 B MX390748 B MX 390748B MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 390748 B MX390748 B MX 390748B
Authority
MX
Mexico
Prior art keywords
sub
sup
methods
compositions
treating ischemic
Prior art date
Application number
MX2018006390A
Other languages
English (en)
Spanish (es)
Other versions
MX2018006390A (es
Inventor
David Elmaleh
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2018006390A publication Critical patent/MX2018006390A/es
Publication of MX390748B publication Critical patent/MX390748B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018006390A 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico. MX390748B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
MX2018006390A MX2018006390A (es) 2019-02-14
MX390748B true MX390748B (es) 2025-03-21

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006390A MX390748B (es) 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
EP3654946A4 (en) 2017-07-20 2021-04-21 AZTherapies, Inc. CROMOLYNE SODIUM AND IBUPROFEN POWDER FORMULATIONS
AU2017442079A1 (en) * 2017-12-04 2020-06-25 The General Hospital Corporation Cromolyn compositions and methods thereof
CA3096545A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
CA3122989A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601380A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
CA2751125C (en) * 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
MX2011009362A (es) * 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
JP2012520311A (ja) * 2009-03-11 2012-09-06 プレキシコン インコーポレーテッド Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体
EP2911664B1 (en) * 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
MX381503B (es) * 2013-05-23 2025-03-12 Aztherapies Inc Métodos para la liberación de cromolina.
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015120389A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
KR20190044647A (ko) * 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포

Also Published As

Publication number Publication date
AU2016359674A1 (en) 2018-06-14
KR20180081812A (ko) 2018-07-17
EP3380095A4 (en) 2019-10-23
JP2018538273A (ja) 2018-12-27
CA3005909A1 (en) 2017-06-01
WO2017091644A1 (en) 2017-06-01
MX2018006390A (es) 2019-02-14
US20220125753A1 (en) 2022-04-28
CN108472275A (zh) 2018-08-31
EP3380095A1 (en) 2018-10-03
US20180344682A1 (en) 2018-12-06
EP3380095B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201890522A1 (ru) Способ получения противогрибковых соединений
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
MX378499B (es) Compuestos antifungicos.
EA201691156A1 (ru) Пирролидиноновые гербициды
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
EA201691439A1 (ru) Пиримидинилоксибензольные производные в качестве гербицидов
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
ECSP16067303A (es) Heteroarilos y usos de estos
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EP3331880A4 (en) N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201792433A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
MX381344B (es) Compuestos antifungicos y procesos para la fabricacion.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EA201691141A1 (ru) Соединения против ccr6
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX382175B (es) Composiciones de profármaco de monometilfumarato
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors